Development of an HPLC method for monitoring of Photofrin II therapy.
OBJECTIVE
To develop and to validate a method to quantify plasma porphyrins after application of Photofrin II, a drug preparation that is used for photodynamic therapy (PDT) and as a radiosensitizer.


METHODS
After solid phase extraction of postdose plasma samples, reversed phase high performance-liquid chromatography with fluorescence detection was performed. Plasma porphyrin concentrations were monitored in five patients that were treated with Photofrin II.


RESULTS
The method proved linear over a wide concentration range, precise, and applicable in a routine clinical laboratory setting.


CONCLUSIONS
The method described here will enable large-scale clinical pharmacokinetic studies on Photofrin II; investigations can now address possible correlations between individual concentrations of drug-derived plasma porphyrins and systemic photosensitivity--representing the main side effect of Photofrin II--with the perspective of individualized light protection regimens after Photofrin II administration.
Vogeser
Michael
M
Institute of Clinical Chemistry, Hospital of the University of Munich, Munich, Germany.
Schaffer
Moshe
M
Egeler
Emil
E
Spöhrer
Ute
U
D000970:Antineoplastic Agents / Q000494:pharmacology*; D002623:Chemistry Techniques, Analytical / Q000379:methods*; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D017323:Dihematoporphyrin Ether / Q000494:pharmacology*; D006801:Humans; D010778:Photochemotherapy; D010949:Plasma / Q000187:drug effects / Q000378:metabolism; D011166:Porphyrins / Q000737:chemistry / Q000378:metabolism; D013997:Time Factors
D000970:Antineoplastic Agents; D011166:Porphyrins; D017323:Dihematoporphyrin Ether